Bill Introduced to Strengthen Protections for Child Antipsychotic Prescriptions

Bill Introduced to Strengthen Protections for Child Antipsychotic Prescriptions - Healthcare Law Update - February 2025 - Brach Eichler
BACK TO INSIGHTS     Articles

2/7/2025

Assembly Bill 5147, introduced in the New Jersey Assembly on December 16, 2024, would require health care providers who are authorized to prescribe psychotropic drugs and participate in NJ FamilyCare to provide information to, and obtain consent from, a parent or guardian before prescribing an antipsychotic drug to a child under the age of 18. Prescribers would be required to provide to the parent or guardian the drug’s Medication Guide, information regarding any evidence-based alternatives to the use of the drug and information on how to use and access the FDA’s tools to publicly report adverse events. Prescribers would be required to obtain a signed consent form from the child’s parent or guardian, indicating that the parent or guardian understands any potential risks or side effects of the drug, is aware of any evidence-based alternatives to the use of the drug and has been informed of the FDA’s tools to report adverse effects.

Click Here to read the entire February 2024 Healthcare Law Update now!

For more information, contact:
John D. Fanburg, Chair | 973.403.3107 | jfanburg@bracheichler.com
Edward Hilzenrath | 973.403.3114 | ehilzenrath@bracheichler.com
Rebecca T. Falk | 973.364.8393 | rfalk@bracheichler.com

*This is intended to provide general information, not legal advice. Please contact the authors if you need specific advice.

Related Practices:   Healthcare Law

Related Industry:   Healthcare